Christian  Hordo net worth and biography

Christian Hordo Biography and Net Worth

Christian Hordo, MBA, is Chief Business Officer at Sana Biotechnology leading the business development, corporate strategy drug development program leadership, and commercial functions.

Christian was most recently a Vice President at Juno Therapeutics, where he was the Multiple Myeloma program lead, responsible for progressing multiple drug candidates, including Juno’s BCMA CAR-T, through preclinical and clinical studies. He was also Juno’s Head of Business Development, where he built a team and led negotiations on multiple successfully executed transactions, including the broad strategic collaboration with Celgene. Prior to Juno, Christian spent five years at Genentech in business development and program leadership, successfully negotiating numerous transactions and leading a cross-functional drug development team for GDC-0134, a first-in-class small molecule for the treatment of ALS.

Christian earned his MBA from Harvard Business School, graduating with high distinction as a Baker Scholar, his MSc in medical genetics and microbiology from the University of Toronto and his BSc in psychology at McGill University.

What is Christian Hordo's net worth?

The estimated net worth of Christian Hordo is at least $2.36 million as of September 9th, 2021. Mr. Hordo owns 1,008,603 shares of Sana Biotechnology stock worth more than $2,360,131 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Hordo may own. Additionally, Mr. Hordo receives a salary of $485,030.00 as EVP at Sana Biotechnology. Learn More about Christian Hordo's net worth.

How old is Christian Hordo?

Mr. Hordo is currently 41 years old. There are 7 older executives and no younger executives at Sana Biotechnology. The oldest executive at Sana Biotechnology is Mr. Bernard J. Cassidy J.D., Executive VP, General Counsel & Corporate Secretary, who is 69 years old. Learn More on Christian Hordo's age.

What is Christian Hordo's salary?

As the EVP of Sana Biotechnology, Inc., Mr. Hordo earns $485,030.00 per year. There are 2 executives that earn more than Mr. Hordo. The highest earning executive at Sana Biotechnology is Dr. Steven D. Harr M.D., President, CEO & Director, who commands a salary of $1,040,000.00 per year. Learn More on Christian Hordo's salary.

How do I contact Christian Hordo?

The corporate mailing address for Mr. Hordo and other Sana Biotechnology executives is 188 EAST BLAINE STREET SUIT 400, SEATTLE WA, 98102. Sana Biotechnology can also be reached via phone at 206-701-7914 and via email at [email protected]. Learn More on Christian Hordo's contact information.

Has Christian Hordo been buying or selling shares of Sana Biotechnology?

Christian Hordo has not been actively trading shares of Sana Biotechnology during the last quarter. Most recently, Christian Hordo sold 64,671 shares of the business's stock in a transaction on Thursday, September 9th. The shares were sold at an average price of $25.01, for a transaction totalling $1,617,421.71. Following the completion of the sale, the executive vice president now directly owns 1,008,603 shares of the company's stock, valued at $25,225,161.03. Learn More on Christian Hordo's trading history.

Who are Sana Biotechnology's active insiders?

Sana Biotechnology's insider roster includes Nathan . (Exec. VP & CFO ), Steven Harr (Pres), and Christian Hordo (EVP). Learn More on Sana Biotechnology's active insiders.

Are insiders buying or selling shares of Sana Biotechnology?

During the last year, Sana Biotechnology insiders bought shares 1 times. They purchased a total of 1,818,181 shares worth more than $9,999,995.50. During the last year, insiders at the sold shares 1 times. They sold a total of 150,000 shares worth more than $612,000.00. The most recent insider tranaction occured on September, 24th when Director Richard Mulligan sold 150,000 shares worth more than $612,000.00. Insiders at Sana Biotechnology own 31.1% of the company. Learn More about insider trades at Sana Biotechnology.

Information on this page was last updated on 9/24/2024.

Christian Hordo Insider Trading History at Sana Biotechnology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/9/2021Sell64,671$25.01$1,617,421.711,008,603View SEC Filing Icon  
9/2/2021Sell7,958$25.00$198,950.00977,356View SEC Filing Icon  
8/30/2021Sell2,300$25.01$57,523.00976,100View SEC Filing Icon  
See Full Table

Christian Hordo Buying and Selling Activity at Sana Biotechnology

This chart shows Christian Hordo's buying and selling at Sana Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sana Biotechnology Company Overview

Sana Biotechnology logo
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $2.34
Low: $2.34
High: $2.60

50 Day Range

MA: $3.77
Low: $2.34
High: $4.62

2 Week Range

Now: $2.34
Low: $2.29
High: $12.00

Volume

980,537 shs

Average Volume

2,142,411 shs

Market Capitalization

$522.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44